nct_id: NCT06172478
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-12-15'
study_start_date: '2024-02-26'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: HER3-DXd'
long_title: 'HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort,
  Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402)
  in Subjects With Locally Advanced or Metastatic Solid Tumors'
last_updated: '2025-10-14'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: Daiichi Sankyo
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 740
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- Inclusion Criteria
- 'Participants must meet all of the following criteria to be eligible for enrollment
  into the study:'
- 1. Sign and date the informed consent form prior to the start of any study-specific
  qualification procedures. A separate tissue screening consent will be obtained from
  all subjects to meet the baseline tumor tissue requirement.
- "2. Participants aged \u226518 years (follow local regulatory requirements if the\
  \ legal age of consent for study participation is \\>18 years old)."
- '3. Has locally advanced unresectable or metastatic disease (not curable by surgery
  or radiation) as follows:'
- Cutaneous (acral and non-acral) melanoma
- 1. Histologically or cytologically confirmed cutaneous (acral or non-acral) melanoma
- "2. Disease progression while on or after having received treatment with \u2265\
  1 prior line of anti-programmed cell death protein (PD-1) or anti-programmed death-ligand\
  \ 1 (PD-L1) based therapy (previous use of other immune checkpoint inhibitors \\\
  [ICIs\\] \\[ie, anti-CTLA4, anti- LAG-3\\] is acceptable). Prior anti-PD-(L)1 therapy\
  \ in the adjuvant setting is allowed if there is recurrence within 12 weeks of the\
  \ last dose. If the participant had BRAFm melanoma, they must have had disease progression\
  \ on BRAF/MEK inhibitor therapy as well."
- Squamous cell carcinomas of the head and neck
- 3. Squamous cell carcinoma of the head and neck (with a primary location of oral
  cavity,oropharynx, larynx, hypopharynx) that is human papillomavirus (HPV) positive
  or negative (as determined by local standard). Excludes tumor location in the nasopharynx,
  nasal cavity, paranasal sinuses, and unknown primary locations.
- "4. Disease progression after having received treatment with \u22651 and \\<3 prior\
  \ lines of systemic therapy in the unresectable recurrent or metastatic setting."
- Must have had disease progression on anti-PD-(L)1 (either as monotherapy or in combination
  with chemotherapy or other therapies). Must also have had disease progression on
  a platinum-based chemotherapy (PBC) regimen either in the recurrent or metastatic
  setting or in the locally advanced setting with curative intent.
- Gastric or GEJ adenocarcinoma
- 5. Tumor tissue must be confirmed as negative for HER2 expression (immunohistochemistry
  \[IHC\] 0/1+ or IHC 2+/in situ hybridization negative) as classified by American
  Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines
  and determined prior to enrollment by assessment in a local laboratory that is Clinical
  Laboratory Improvement Amendments certified (US sites) or accredited based on specific
  country regulations.
- "6. Disease progression after having received treatment with \u22652 prior lines\
  \ of therapy that include PBC with or without anti-PD-1 therapy."
- Ovarian Carcinoma
- 7. Pathologically documented high-grade serous epithelial ovarian cancer, primary
  peritoneal cancer, or fallopian tube cancer.
- "8. Documented disease progression \u22654 weeks after the last dose of PBC and\
  \ \\<6 months of last dose of PBC in the advanced or metastatic setting. Prior use\
  \ of folate reductase alpha targeting antibody-drug conjugate (ADC) (ie, mirvetuximab\
  \ soravtansine) is allowed."
- Cervical Cancer
- 9. Pathologically or cytologically documented recurrent or persistent squamous,
  adenosquamous, or adenocarcinoma of the uterine cervix.
- "10. Disease progression after having received \u22651 line of systemic therapy\
  \ in the recurrent or metastatic setting. This may include prior anti-PD-(L)1 treatment\
  \ and/or tissue factor directed ADC (tisotumab vedotin \\[TV\\]) per regional standard\
  \ of care."
- Endometrial Cancer
- 11. Pathologically or cytologically documented endometrial cancer (carcinoma of
  any histological sub-type or endometrial carcinosarcoma), irrespective of microsatellite
  instability (MSI) or mismatch repair (MMR) status.
- "12. Documented disease progression after having received \u22651 prior line of\
  \ therapy (maximum of 3) PBC containing systemic treatment and an anti-PD(L)-1 therapy-containing\
  \ regimen (combined or sequential) in the advanced/metastatic setting."
- Bladder Cancer
- 13. Pathologically or cytologically documented locally advanced/unresectable or
  metastatic urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra.
  Histological variants are allowed if urothelial histology is predominant. Small
  cell/neuroendocrine tumors are not allowed even if mixed histology.
- "14. Relapsed or progressed after treatment with \u22651 prior line of therapy (maximum\
  \ of 3) that contains anti-PD-(L)1 therapy in the perioperative or metastatic setting.\
  \ At least 1 line of therapy must also contain one of the following treatment modalities:\
  \ chemotherapy or enfortumab vedotin. Prior fibroblast growth factor receptor (FGFR)-inhibitor\
  \ treatment for those who are eligible are allowed."
- '* Required treatments can be given in combination or sequentially'
- '* Prior cisplatin-based therapy or PD-(L)1 inhibitor therapy given for the treatment
  of muscle invasive urothelial carcinoma is counted as 1 line of therapy'
- '* The same regimen administered twice in different disease settings will be counted
  as 1 line of prior therapy'
- '* Participants in the second-line setting who have previously received enfortumab
  vedotin and pembrolizumab in combination can be enrolled.'
- Esophageal Carcinoma
- 15. Pathologically or cytologically documented esophageal squamous cell carcinoma.
- 16. Must have documented disease progression after having received 2 prior lines
  of therapy including previous PBC with or without an anti-PD-1 therapy-containing
  regimen (combined or sequential) in the advanced/metastatic setting.
- Pancreatic Carcinoma
- 17. Pathologically or cytologically documented unresectable or metastatic pancreatic
  adenocarcinoma.
- 18. Relapsed or disease progression after having received 1 prior line of systemic
  therapy in the locally advanced/metastatic setting.
- Prostate Cancer
- 19. Pathologically or cytologically documented unresectable locally advanced or
  metastatic castration-resistant prostate cancer (CRPC).
- 20. Adenocarcinoma of the prostate without neuroendocrine differentiation or small
  cell histology.
- 21. Surgically or medically castrated, with testosterone levels of \<50 ng/dL.
- 22. Documented objective progression as determined by radiographic progression for
  subjects with measurable disease after androgen deprivation.
- "23. Relapsed or disease progression after having received treatment with \u2265\
  1 of the following novel hormonal agents: abiraterone, enzalutamide, apalutamide,\
  \ or darolutamide."
- "24. Relapsed or disease progression after having received \u22651 cytotoxic chemotherapy\
  \ regimen that included a taxane."
- Gastric Cancer 2L
- 25. Must have had gastric or GEJ adenocarcinoma confirmed as negative for HER2 expression
  (IHC 0/1+ or IHC 2+/in situ hybridization negative) as classified by American Society
  of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines and
  determined prior to enrollment by assessment in a local laboratory that is Clinical
  Laboratory Improvement Amendments certified (US sites) or accredited based on specific
  country regulations.
- 26. Disease progression after having received treatment with only 1 prior line of
  systemic anti-cancer therapy that includes 5-FU-based chemotherapy with or without
  an anti-PD-1 therapy. For subjects whose tumors are claudin (CLDN) 18.2 positive,
  treatment with 5-FU based chemotherapy with CLDN18.2 directed therapy in the first-line
  setting is allowed.
- Non-small Cell Lung Cancer aa. Histologically or cytologically documented metastatic
  or locally advanced nonsquamous NSCLC not amenable to curative surgery or radiation
  bb. Documentation of absence of actionable driver mutation (ie, ALK rearrangement,
  BRAF V600E mutation, EGFR-activating mutations \[exon 19 deletion or L858R mutation\],
  EGFR exon 20 insertion mutation, HER2 mutation, KRAS G12C mutation, MET exon 14
  skipping mutation, NTRK 1/2/3 gene fusion, RET rearrangement, or ROS1 rearrangement).
  New testing for these genomic alterations is not required for Screening.
- cc. Relapsed or disease progression after receiving only anti-PD-(L)1 and PBC (ie,
  platinum doublet) administered in combination or sequentially for metastatic disease.
- "Breast Cancer dd. Pathologically documented breast cancer that is assessed as HER2\
  \ negative (IHC2+/ISH-, IHC1+, or IHC0 per ASCO/CAP guidelines), and HR positive\
  \ (either ER and/or PgR positive \\[ER or PgR \u22651%\\] per ASCO/CAP guidelines).\
  \ The HER2 and HR results must be from a tumor sample obtained in the metastatic\
  \ setting."
- ee. Participant must have received one line of chemotherapy for mBC, but not more
  than one line and must have a clinically or radiologically documented evidence of
  tumor progression on or after CDK 4/6 inhibitor combined with endocrine therapy;
  previous treatments with phosphoinositide 3-kinase (PI3K) inhibitors, mammalian
  target of rapamycin (mTOR) inhibitors, protein kinase B (PKB) inhibitors also known
  as AKT-inhibitors and poly ADP ribose polymerase (PARP)-inhibitors are allowed.
- "4. Has \u22651 measurable lesion on CT or MRI as per RECIST v1.1 by investigator\
  \ assessment. Prostate cancer participants with bone only disease may be eligible."
- '5. Provides a pretreatment tumor tissue sample that meets 1 of the following collection
  requirements:'
- "1. Tumor biopsy from \u22651 lesion not previously irradiated and performed since\
  \ progression with the most recent systemic cancer therapy regimen and prior to\
  \ signature of the tissue ICF (ARCHIVAL PRETREATMENT sample)."
- OR
- "2. Newly obtained pretreatment tumor biopsy from \u22651 lesion not previously\
  \ irradiated and amenable to sampling, after signature of tissue ICF (FRESH PRETREATMENT\
  \ sample)"
- 6. Has Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
  at screening.
- Exclude - Exclusion Criteria
- 'Exclude - Participants who meet any of the following criteria will be disqualified
  from entering the study:'
- Exclude - 1. Has HER2-positive gastric cancer as classified by ASCO-CAP guidelines
  and determined prior to enrollment by assessment in a local laboratory that is Clinical
  Laboratory Improvement Amendments certified (US sites) or accredited based on specific
  country regulations.
- Exclude - 2. Has nasopharyngeal cancer.
- Exclude - 3. Has mucosal or uveal melanoma.
- Exclude - 4. Has a history of (non-infectious) interstitial lung disease (ILD),
  that required corticosteroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis
  cannot be ruled out by imaging at screening.
- Exclude - 5. Has clinically severe respiratory compromise (based on the investigator's
  assessment) resulting from intercurrent pulmonary illnesses
- Exclude - 6. Is receiving chronic systemic corticosteroids dosed at \>10 mg prednisone
  daily or equivalent anti-inflammatory activity or any form of immunosuppressive
  therapy prior to Cycle 1 Day 1.
- Exclude - Participants who require use of bronchodilators, inhaled or topical steroids,
  or local steroid injections may be included in the study.
- Exclude - 7. Had prior treatment with an anti-HER3 antibody and/or antibody-drug
  conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase
  I inhibitor (eg, trastuzumab deruxtecan).
- 'Exclude - 8. Has history of other active malignancy within 3 years prior to Cycle
  1 Day 1, except the following:'
- Exclude - 1. Adequately treated nonmelanoma skin cancer
- Exclude - 2. Adequately treated intraepithelial carcinoma of the cervix
- Exclude - 3. Any other curatively treated in situ disease
- Exclude - 9. Has any evidence of severe or uncontrolled diseases (eg, active bleeding
  diatheses, active serious infection) psychiatric illness/social situations, geographical
  factors, substance abuse, or other factors that, in the investigator's opinion,
  make it high risk for the subject to participate in the study or that would jeopardize
  compliance with the protocol
- Exclude - 10. Has previously received topoisomerase-1 inhibitors (e.g., irinotecan)
  treatment in the advanced or metastatic disease setting.
short_title: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid
  Tumors
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Daiichi Sankyo
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This is a proof-of-concept study designed to investigate HER3-DXd monotherapy
  in locally advanced unresectable or metastatic solid tumors. The study is enrolling
  cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas
  of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical
  cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma,
  prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: HER3-DXd Monotherapy
      arm_internal_id: 0
      arm_description: Participants with locally advanced unresectable or metastatic
        cancer (melanoma, head and neck, gastric cancer, ovarian carcinoma, cervical
        cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic
        carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast
        cancer) will receive an intravenous infusion of HER3-DXd monotherapy 5.6 mg/kg
        every 3 weeks (Q3W).
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: HER3-DXd'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        her2_status: Negative
        er_status: Positive
        pr_status: Positive
        disease_status:
        - Locally Advanced
        - Metastatic
        - Unresectable
        - Recurrent
        oncotree_primary_diagnosis: _SOLID_
